Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nemysis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Chinese Patent for IHAT, the Novel Iron Nanoparticulate Supplement for Iron Deficiency (ID) and Iron Deficiency With Anemia","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"IRELAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II"},{"orgOrder":0,"company":"Nemysis","sponsor":"Bruno Farmaceutici","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Signs IHAT Sales and Marketing Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"},{"orgOrder":0,"company":"Nemysis","sponsor":"European Union","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Receives EU Horizon Grant Funding for E40","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Nemysis","sponsor":"Kolinpharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nemysis Limited Signs with Kolinpharma SpA an IHAT Sales and Marketing Agreement","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Nemysis

    Menu

    Nemysis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Nemysis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nemysis Limited Signs with Kolinpharma SpA an IHAT Sales and Marketing Agreement

              Details:

              Under the agreement, Kolinpharma will use its existing sales network and relationships with relevant clinical communities to market Iron Hydroxide Adipate Tartrate (IHAT), an oral iron supplementation product for iron deficiency, under its brand KIPFeR.

              Lead Product(s): Iron Hydroxide Adipate Tartrate

              Therapeutic Area: Hematology Product Name: KIPFeR

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Kolinpharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 10, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nemysis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nemysis Limited Receives EU Horizon Grant Funding for E40

              Details:

              The net proceeds will fund the completion of research & development to Market Authorization of Nemysis' novel E40 (endoprotease 40 glutenase) for the prevention of symptomatic gluten exposure in gluten intolerance and sensitivity.

              Lead Product(s): Endoprotease 40 Glutenase

              Therapeutic Area: Gastroenterology Product Name: E40

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: European Union

              Deal Size: $2.7 million Upfront Cash: Undisclosed

              Deal Type: Funding November 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nemysis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nemysis Limited Signs IHAT Sales and Marketing Agreement

              Details:

              Under the agreement, Bruno will use its existing sales network and relationships with relevant clinical communities to market IHAT (iron hydroxide adipate tartrate), an oral iron supplementation product, under its own brand.

              Lead Product(s): Iron Hydroxide Adipate Tartrate

              Therapeutic Area: Hematology Product Name: IHAT

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bruno Farmaceutici

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nemysis

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Chinese Patent for IHAT, the Novel Iron Nanoparticulate Supplement for Iron Deficiency (ID) and Iron Deficiency With Anemia

              Details:

              The patent claims describe methods for producing IHAT (Iron Hydroxide Adipate Tartrate), where Generally Recognised As Safe (GRAS) organic acids, and particularly Tartaric and Adipic acids, are used to modify the ferrihydrite nanocore of ferritin.

              Lead Product(s): Iron Hydroxide Adipate Tartrate

              Therapeutic Area: Hematology Product Name: IHAT-02

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY